Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 3/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 6/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741209 | 0.79 | PDGFRB (0.58) | GUSBF7F3OPRM1PDGFRB | |
| SCHEMBL1608873 | 0.77 | IDO1 (0.53) | F7F3PDGFRBPDGFRAPYGL | |
| SCHEMBL1608887 | 0.73 | GUSB (0.58) | GUSBPYGLNPC1HRH4 | |
| SCHEMBL26213276 | 0.72 | KDM4E (0.67) | F7F3PDGFRBPYGLFLT3 | |
| SCHEMBL6400662 | 0.71 | GUSB (0.65) | GUSBF7F3OPRM1PYGL | |
| SCHEMBL5207050 | 0.69 | HRH4 (0.59) | GUSBPDGFRBPDGFRAMEN1KMT2A | |
| SCHEMBL6323164 | 0.68 | HRH4 (0.58) | GUSBPDGFRBPDGFRALGALS8LGALS3 | |
| SCHEMBL764543 | 0.68 | F7 (0.72) | GUSBF7F3PYGLFLT3 | |
| SCHEMBL1608567 | 0.68 | GUSB (0.60) | GUSBPYGLHRH4 | |
| SCHEMBL3963537 | 0.67 | F7 (0.66) | F7F3PDGFRBPYGLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086885-A1 | Indole-2-carboxylic acid amides | PROSIDION LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086885-A1 | Indole-2-carboxylic acid amides | IDO2, IDO1, CPT1A | GUSB 2784/4885F7 2611/4885F3 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.